Flexion Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.3M
Doctors Paid
10,183
Transactions
37,550
2020 Total
$2.1M
Payment Breakdown by Category
Research$6.6M (58.2%)
Consulting$1.8M (15.8%)
Food & Beverage$867,939 (7.7%)
Travel$349,908 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 183 | 58.2% |
| Consulting Fee | $1.8M | 502 | 15.8% |
| Honoraria | $1.5M | 613 | 13.5% |
| Food and Beverage | $867,939 | 34,655 | 7.7% |
| Travel and Lodging | $349,908 | 976 | 3.1% |
| Grant | $100,000 | 2 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $91,271 | 29 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,942 | 246 | 0.1% |
| Education | $4,294 | 344 | 0.0% |
Payments by Type
Research
$6.6M
183 transactions
General
$4.7M
37,367 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients with Osteoarthritis of the Knee | $2.6M | 0 | 22 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis | $1.1M | 0 | 58 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis | $661,744 | 0 | 36 |
| A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients with Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip | $386,201 | 0 | 7 |
| An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients with Osteoarthritis of the Knee | $379,060 | 0 | 19 |
| Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee | $322,211 | 0 | 3 |
| Success of Long-acting Anti-inflammatories after anterior cruciate ligament and Meniscal injury SLAM | $194,996 | 1 | 1 |
| Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip | $184,942 | 0 | 11 |
| Benefits of IA Injections | $116,025 | 0 | 2 |
| A study of the Effect of Intraarticular Corticosteroid on Metabolic Syndrome Biomarkers A Pilot Feasibility Study | $109,806 | 1 | 1 |
| Zilretta vs. TAcs | $101,600 | 0 | 1 |
| Rotator Cuff | $82,453 | 0 | 1 |
| Effect of ZILRETTA Injection on Neuromuscular Function, Gait Biomechanics and Physical Performance | $74,012 | 0 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder | $57,625 | 0 | 10 |
| Success of Long-acting Anti-inflammatories after anterior cruciate ligament and Meniscal injury (SLAM) | $48,749 | 0 | 1 |
| An open-label pilot study of the effect of intra-articular bilateral knee injections of Zilretta (FX006) on OARSI recommended physical performance measures in adults with knee osteoarthritis. | $45,156 | 0 | 1 |
| Patient- and Physician-Perceived Barriers to and Benefits of Intraarticular Injections for Osteoarthritis: A Qualitative Study | $29,006 | 0 | 1 |
| A study of the Effect of Intraarticular Corticosteroid on Metabolic Syndrome Biomarkers (A Pilot / Feasibility Study) | $27,452 | 0 | 1 |
| A Stratified Investigation of a Single Injection of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for Symptomatic Relief in Patients with Idiopathic Adhesive Capsulitis of the Shoulder. | $24,529 | 0 | 1 |
| A Randomized, Open-label, Parallel Group Study in Patients with Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration into Both Knees of either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) | $20,687 | 0 | 3 |
| Zilretta for Shoulder IAC | $20,441 | 0 | 1 |
| Study to assess the safety and efficacy of FX006 administered to patients with greater trochanteric bursitis | $15,439 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Unknown Provider | — | — | $37,783 | $0 |
| Elizabeth Batterton, M.d, M.D | Sports Medicine | Phoenix, AZ | $37,288 | $0 |
| Dr. Ritesh Shah, M.d, M.D | Orthopaedic Surgery | Morton Grove, IL | $36,072 | $0 |
| Kevin Murphy, M.d, M.D | Specialist | Tualatin, OR | $35,464 | $0 |
| Petros Efthimiou, Md, MD | Rheumatology | New York, NY | $35,394 | $0 |
| Dr. Alexander Sah, Md, MD | Adult Reconstructive Orthopaedic Surgery | Fremont, CA | $34,956 | $0 |
| Michael Axe, Md, MD | Orthopaedic Surgery | Newark, DE | $34,402 | $0 |
| Dr. Joseph Zarzour, M.d, M.D | Orthopaedic Surgery | Mobile, AL | $32,750 | $0 |
| Dr. Padraic Obma, M.d, M.D | Sports Medicine | Green Bay, WI | $32,240 | $0 |
| Chad Hanson, M.d, M.D | Sports Medicine | Las Vegas, NV | $30,949 | $0 |
| Vibeke Strand, M.d, M.D | Rheumatology | Portola Valley, CA | $30,679 | $0 |
| Alan Kivitz, Md, MD | Rheumatology | Duncansville, PA | $29,935 | $0 |
| Dr. Rainer Vogel, M.d, M.D | Anesthesiology | Henderson, NV | $28,486 | $0 |
| Terry Clyburn, M.d.,P.a, M.D.,P.A | Orthopaedic Surgery | Houston, TX | $27,557 | $0 |
| Dr. Bradley Boyd, D.o, D.O | Orthopaedic Surgery | Fairfax, VA | $27,323 | $0 |
| Dr. Allan Gibofsky, Md, MD | Rheumatology | New York, NY | $25,735 | $0 |
| Dr. Matthew Carroll, M.d, M.D | Rheumatology | Pascagoula, MS | $25,230 | $0 |
| Justin Classie, M.d, M.D | Sports Medicine | Fresh Meadows, NY | $24,414 | $0 |
| Rajiv Pandya, Md, MD | Orthopaedic Surgery | Stockbridge, GA | $24,348 | $0 |
| Dr. Theresa Lawrence-Ford, M.d, M.D | Rheumatology | Lawrenceville, GA | $24,057 | $0 |
| Dr. Robert Kennon, Md, MD | Orthopaedic Surgery | Middlebury, CT | $23,944 | $0 |
| Dr. Jose Ortega, Md, MD | Sports Medicine | Birmingham, AL | $21,596 | $0 |
| Dr. Michael Kelly, Md, MD | Orthopaedic Surgery | Hackensack, NJ | $21,492 | $0 |
| Sanjay Sinha, Md, MD | Anesthesiology | Hartford, CT | $21,374 | $0 |
| Steven Morton, D.o, D.O | Orthopaedic Surgery | Breese, IL | $21,246 | $0 |
About Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. has made $11.3M in payments to 10,183 healthcare providers, recorded across 37,550 transactions in the CMS Open Payments database. In 2020, the company paid $2.1M. The top product by payment volume is Zilretta ($10.0M).
Payments were distributed across 117 medical specialties. The top specialty by payment amount is Orthopaedic Surgery ($2.3M to 3,632 doctors).
Payment categories include: Food & Beverage ($867,939), Consulting ($1.8M), Research ($6.6M), Travel & Lodging ($349,908).
Flexion Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.